Kardigan (KARD) Stock Price & Analysis
AI Analysis
SnapshotKardigan is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 73/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~157% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Kardigan, Inc. (KARD) last printed $15.18. Equity value is $1.36B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2025 |
|---|
| $0.00 |
About
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.